ArticleVaccines2025
Evaluation of Immunogenicity of an Orf Virus Vector-Based Vaccine Delivery Platform in Sheep.
Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectiveVirus-based vaccine vectors have been widely utilised in commercial vaccines, predominantly for virus infections. They also offer promise for bacterial diseases, for which many vaccines are sub-optimal or ineffective. It is well-established for chlamydial infections, including ovine enzootic abortion, that the major outer membrane protein (MOMP) antigen is protective. Immune responses strongly associated with controlling
methodsA study was conducted to compare the ability of a modified Orf virus vector directly with a modified sheep maedi visna virus vector to deliver the
resultsSerological anti-MOMP antibodies and cellular recall responses of peripheral blood mononuclear cells to the native
conclusionsBoth live and inactivated vaccines have the potential to be a platform technology for deployment in sheep. This addresses a notable gap in veterinary vaccine development where the induction of both humoral responses and cellular responses is required without using an adjuvant. The successful use of the MOMP candidate antigen suggests potential utility for bacterial disease deployment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.